The iPSC industry is rapidly expanding, following the first iPSC trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, and the announcement of an iPSC cellular therapy clinic scheduled to open in 2019. With iPSC patent dominance continuing to cluster in specific geographic regions, clinical trial and scientific publication trends are giving clear indicators of what may happen in the industry in 2015 and beyond.
iPSC Report Applications
This global strategic report is produced for:
- Management of Stem Cell Product Companies
- Management of Stem Cell Therapy Companies
- Stem Cell Industry Investors